Method for inhibiting coronavirus infection and replication

Abstract

Disclosed herein is a method for inhibiting coronavirus infection, including administering to a subject in need thereof an effective amount of pioglitazone or a pharmaceutically acceptable salt thereof. Also disclosed is a method for inhibiting coronavirus replication, including contacting a coronavirus with pioglitazone or a pharmaceutically acceptable salt thereof.

What is claimed is: 
     
         1 . A method for inhibiting coronavirus infection, comprising administering to a subject in need thereof an effective amount of pioglitazone or a pharmaceutically acceptable salt thereof. 
     
     
         2 . The method as claimed in  claim 1 , wherein the coronavirus infection is caused by a coronavirus selected from the group consisting of a member of  Alphacoronavirus  genus, a member of  Betacorovirus  genus, a member of  Gammacoronavirus  genus, a member of  Deltacoronavirus  genus, and combinations thereof. 
     
     
         3 . The method as claimed in  claim 2 , wherein the coronavirus is selected from the group consisting of bat coronavirus CDPHE 15, bat coronavirus HKU10 , Rhinolopus ferrumequinum alphacoronavirus  HuB-2013, human coronavirus 229E (HCoV-229E), Lucheng Rn rat coronavirus, mink coronavirus 1 , Miniopterus  bat coronavirus 1 , Miniopterus  bat coronavirus HKU8,  Myotis ricketti alphacoronavirus  Sax-2011 , Nyctalus velutinus alphacoronavirus  SC-2013,  Pipistrellus kuhlii  coronavirus 3398, porcine epidemic diarrhea virus,  Scotophilus  bat coronavirus 512 , Rhinolophus  bat coronavirus HKU2, human coronavirus NL63, NL63-related bat coronavirus strain BtKYNL63-9b,  Sorex araneus  coronavirus T14 , Suncus murinus  coronavirus X74,  Alphacoronavirus  1, bovine coronavirus, human coronavirus OC43 (HCoV-OC43),  China rattus  coronavirus HKU24, human coronavirus HKU1, murine coronavirus,  Myodes  coronavirus 2JL14, bat Hp-betacoronavirus Zhejiang 2013, Hedgehog coronavirus 1, Middle East respiratory syndrome-related coronavirus,  Pipistrellus  bat coronavirus HKU5,  Tylonycteris  bat coronavirus HKU4 , Eidolon  bat coronavirus C704 , Rousettus  bat coronavirus GCCDC1 , Rousettus  bat coronavirus HKU9, severe acute respiratory syndrome coronavirus (SARS-CoV), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), bat SARS-like coronavirus WIV1, and combinations thereof. 
     
     
         4 . The method as claimed in  claim 3 , wherein the coronavirus is HCoV-229E. 
     
     
         5 . The method as claimed in  claim 3 , wherein the coronavirus is HCoV-OC43. 
     
     
         6 . The method as claimed in  claim 3 , wherein the coronavirus is SARS-CoV-2. 
     
     
         7 . The method as claimed in  claim 1 , wherein the pioglitazone or the pharmaceutically acceptable salt thereof is in a dosage form for oral administration. 
     
     
         8 . A method for inhibiting coronavirus replication, comprising contacting a coronavirus with pioglitazone or a pharmaceutically acceptable salt thereof. 
     
     
         9 . The method as claimed in  claim 8 , wherein the coronavirus is selected from the group consisting of a member of  Alphacoronavirus  genus, a member of  Betacorovirus  genus, a member of  Gammacoronavirus  genus, a member of  Deltacoronavirus  genus, and combinations thereof. 
     
     
         10 . The method as claimed in  claim 9 , wherein the coronavirus is selected from the group consisting of bat coronavirus CDPHE 15, bat coronavirus HKU10 , Rhinolopus ferrumequinum alphacoronavirus  HuB-2013, human coronavirus 229E (HCoV-229E), Lucheng Rn rat coronavirus, mink coronavirus 1 , Miniopterus  bat coronavirus 1 , Miniopterus  bat coronavirus HKU8,  Myotis ricketti alphacoronavirus  Sax-2011 , Nyctalus velutinus alphacoronavirus  SC-2013,  Pipistrellus kuhlii  coronavirus 3398, porcine epidemic diarrhea virus,  Scotophilus  bat coronavirus 512 , Rhinolophus  bat coronavirus HKU2, human coronavirus NL63, NL63-related bat coronavirus strain BtKYNL63-9b,  Sorex araneus  coronavirus T14 , Suncus murinus  coronavirus X74 , Alphacoronavirus  1, bovine coronavirus, human coronavirus OC43 (HCoV-OC43), China  Rattus  coronavirus HKU24, human coronavirus HKU1, murine coronavirus,  Myodes  coronavirus 2JL14, bat Hp-betacoronavirus  Zhejiang  2013, Hedgehog coronavirus 1, Middle East respiratory syndrome-related coronavirus,  Pipistrellus  bat coronavirus HKU5,  Tylonycteris  bat coronavirus HKU4 , Eidolon  bat coronavirus C704 , Rousettus  bat coronavirus GCCDC1 , Rousettus  bat coronavirus HKU9, severe acute respiratory syndrome coronavirus (SARS-CoV), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), bat SARS-like coronavirus WIV1, and combinations thereof. 
     
     
         11 . The method as claimed in  claim 10 , wherein the coronavirus is HCoV-229E. 
     
     
         12 . The method as claimed in  claim 10 , wherein the coronavirus is HCoV-OC43. 
     
     
         13 . The method as claimed in  claim 10 , wherein the coronavirus is SARS-CoV-2.